The molecular mechanism of the tyrosine kinase inhibitor (TKI) resistant lung adenocarcinoma is currently unclear, and the role of methylated adenosine at the N6 position in the resistance of cancer stem cells (CSCs) therapy is unknown. This study identified a novel and effective strategy to enhance TKIs therapy response. We first confirmed the sensitization of Metformin enforcing on Osimertinib treatment and revealed the mature miRNAs signatures of the Osimertinib resistant H1975 and HCC827 cells. Let-7b expression was stimulated when adding Metformin and then increasing the therapy sensitivity by decreasing the stem cell groups expanding. Methyltransferase-like 3 (METTL3) increased the pri-Let-7b, decreased both the pre-Let-7b and mature Let-7b, attenuating the Let-7b controlling of stem cell renewal. The addition of Metformin increased the bindings of DNA methyltransferase-3a/b (DNMT3a/b) to the METTL3 promoter. With the help of the readers of NKAP and HNRNPA2B1, the cluster mediated m6A formation on pri-Let-7b processing increased the mature Let-7b, the key player in suppressing Notch signaling and re-captivating Osimertinib treatment. We revealed that the maturation processing signaling stimulated the methylation regulation of the miRNAs, and may determine the stemness control of the therapy resistance. Our findings may open up future drug development, targeting this pathway for lung cancer patients.

Keywords: therapy resistance, cancer stem-like cells, tyrosine kinase inhibitor, n6-methyladenosine, miRNAs maturation

INTRODUCTION

Lung cancer is the leading cause of cancer-related death worldwide (1, 2), and early detection, early diagnosis, and early treatment are key to its treatment (3, 4). Many steps are taken in China for lung cancer prevention (5–7). Therapy strategies against NSCLC could be classified as chemotherapy, radiotherapy, targeted therapy, and immunotherapy, and targeting therapy of EGFR-tyrosine kinase
inhibitors (TKIs) is continuously gaining prominence in research (8). However, patients can encounter resistance, and therapy eventually fails (9, 10). The TKIs have been applied in clinical treatments for years with successful delivery strategies. One commonly encountered problem is the emergence of resistance to the first generation of TKIs due to the acquired EGFR mutation (exon 18, 19, 21) and L858R/T790M point mutation (10–12). This can be managed by the third generation EGFR inhibitors such as Osimertinib, which effectively prolongs free survival (PFS) and the overall survival (OS) of advanced or resistant NSCLC patients. The ongoing studies will determine whether the Osimertinib can be used as first line treatment, for now, the drug is also believed to be active in NSCLC patients with brain metastasis (13). However, there is no drug available currently to treat or delay resistance to Osimertinib.

The lack of effective treatment for Osimertinib resistant tumors was due to a poor understanding of the factors contributing to therapy response. Cancer stem-like cells (CSCs), also known as cancer initiating cells, function to generate the malignancy group and contribute to therapy resistance (10–12). In recent years, our focus has been on the non-coding RNAs controlling the stem cell renewal, and we observed that mature miRNAs determined stem cell fate by many mechanisms (13). In this study, we tentatively explored the latent roles of miRNAs in Osimertinib treatment response and tried to explore methylation related miRNA maturation in the generation of resistance. We discovered that Metformin can regulate the self-renewal of lung cancer stem cells and their malignant phenotypes. Our observation will pave the way for future drug development using metformin to address the resistance to EGFR TKIs and may lead to better lung cancer therapy in both metastatic and adjuvant settings.

METHODS

Cells culturing and Osimertinib Resistant Cells Establishment

The lung adenocarcinoma cell lines of H1975 and HCC827 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100 µg/mL penicillin, and 100 µg/mL streptomycin. Cells were maintained in an incubator with 5% CO₂ at 37°C. We established the Osimertinib resistant H1975 cells (H1975OR) and the resistant HCC827 cells (HCC827OR) by gradually increasing concentrations of Osimertinib for 72 hours with a recovery period between treatments, as described in detail in the results section.

RNA Microarray, qRT-PCR, and Data Analysis

Total RNAs were extracted by using Trizol reagent (Invitrogen, CA, USA), according to the manufacturer’s instructions, and the arrays were scanned to images using the Agilent Scanner G2505SC. Data were normalized and processed using the R software Limma-package. The differentially expressed miRNAs were screened through fold change>2. For qRT-PCR, the total extracted RNAs were reverse transcribed using a PrimeScript RT reagent Kit with gDNA Eraser (TAKARA, Dalian, China), and the complementary DNA templates were amplified by using SYBR Premix Ex Taq (TAKARA), as previously reported (14, 15). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was conducted to evaluate the attributes of miRNAs in pathways (https://www.genome.jp/kegg/).

**Stem-Like Cell Isolation and Functional Identification**

The ALDH1A1 phenotype is proven to be one of the most indicative markers referring to the stem cells group. Specifically, ALDEFLUOR is supplied in the form of Bodipy-2-Aminoacidethy Diethyl-Acetal, which by itself is not a substrate of ALDH, and briefly, A) ALDEFLUOR ACTIVATION, B) CELL SAMPLE PREPARATION, C) ALDEFLUOR ASSAY, D) FLOW-CYTOMETER SET-UP AND DATA ACQUISITION, according to the manufacturing information of ALDEFLUOR Kit (Stemcell Technology, Canada). Stem cell enrichment was achieved by spheres culturing in suspension cultivation with a special made medium as previously proven in our earlier study (14, 16).

**RNA Immunoprecipitation and Chromatin Immunoprecipitation Assays**

Antibodies against EGFR (1:3000, EP38Y, ab25894, Rabbit monoclonal, Abcam), p-EGFR (Tyr-845 phosphorylated EGFR, 1:1000, 12A3, sc-57542, mouse monoclonal, Santa Cruz), Notch1 (1:3000, ab65297, Rabbit polyclonal, Abcam), Notch2 (1:3000, ab137665, Rabbit polyclonal, Abcam), NCSTN (1:1000, 14071-1-AP, Nicastrin Polyclonal antibody, Protein-tech), Vinculin (1:5000, #4650, Rabbit polyclonal, Cell Signaling), OCT-4 (1:5000, #2750S, Rabbit polyclonal, Cell Signaling), Snail1 (1:1000, 13099-1-AP, Rabbit polyclonal, Thermo-Fisher Scientific), Klf-4 (1:1000, 11880-1-AP, KLF4 Polyclonal antibody, Rabbit polyclonal, Protein-tech), WAP (1:500, D-7, sc-387280, mouse monoclonal, Santa Cruz), METTL3 (1:3000, 15073-1-AP, METTL3 Polyclonal antibody, Rabbit polyclonal, Protein-tech), METTL14 (1:2000, 26158-1-AP, METTL14 Polyclonal antibody, Rabbit polyclonal, Protein-tech), NKP1 (1:3000, ab229125, C-Terminal, Rabbit polyclonal, Abcam), HNRNPA2B1 (1:5000, DP3B3, ab6102, Mouse monoclonal, Abcam), DGC8R (1:3000, PA5-78510, Rabbit polyclonal, Invitrogen, Thermo-Fisher), DROSHA (1:1000, ab58859, Goat Polyclonal, Abcam), were used in the study and were described in detail for the following application.

RNA immunoprecipitation assays (RIP) were performed using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (17–700, Millipore, Sigma-Aldrich). Total RNA and isotype control for each antibody was assayed as input control and IgG respectively, and simultaneously, the co-precipitated RNAs were detected by qRT-PCR. To detect the m6A level in Let-7b, total RNAs were subjected to ribosome RNA depletion using the Ribo-Zero Gold rRNA Removal Kit.
(Illumina) first, and Ribo-off RNAs were subjected to RNA Fragmentation Reagents (AM8740, Ambion, Applied Biosystem). Precipitation was performed using anti-m6A antibody (1:1000, #202003, Rabbit polyclonal, Synaptic Systems GmbH, SYSY) previously bound to magnetic Dynabeads using a Co-Immunoprecipitation Kit (14321D, Thermo-Fisher), and then incubated with fragmented RNAs.

For western blot analysis, the proteins from cell extracts were separated by 10% SDS-PAGE electrophoresis and cut prior to hybridization. After being transferred onto PVDF membranes, the protein adherent membranes were then incubated with specific antibodies. ECL Blotting Detection Reagents (Merck Millipore) were used for final blot development.

Chromatin immunoprecipitation (ChIP) assays were performed using the kit (#17-295, Sigma-Aldrich, MERCK). Cells were cross-linked with 1% formaldehyde, lysed, and sonicated on ice to generate DNA fragments, pre-cleared DNA of each sample was saved as input fraction and then used for immunoprecipitation with specific antibodies, as were listed above. IgG was included as a nonspecific control.

**DNA Methylation Analysis**

DNA from different groups was extracted using the TIANamp Genomic DNA Kit (DP130227, #DP304, TIANGEN), and purified DNA samples were subsequently subject to bisulfite conversion using the EpiTect Fast Bisulfite Conversion Kits (#59826, TIANGEN). Methylation-specific PCR was performed using EpiTect Methyl-Light PCR Kits (#59436, TIANGEN) with specific primers targeting the CpG island in the METTL3 promoter.

**Statistical Analysis**

The relative expression of RNA was calculated using the 2^(-ΔΔCt) method, where Ct represents the threshold cycle. Graph-Pad Prism 6.0 was used for data analysis and for plotting. Wilcoxon matched pairs tests were used to compare the circRNA expression levels of two groups. p<0.05 was considered statistically significant.

**RESULTS**

**Alterations in Biology and Proliferation Patterns of the Osimertinib Resistant Lung Cancer Adenocarcinoma Cells**

The drug sensitivity was checked and analyzed using data from Genomics of Drug Sensitivity in Cancer at the SANGER site (https://www.cancerrxgene.org/). H1975 cells were originally sensitive to Osimertinib treatment (Supplemental Figure 1), and all related therapeutic agents were listed with a specific score, as listed in Supplemental Figure 1B. The IC_{50} value of Osimertinib for H1975 was calculated approximately at 60 nM (Supplemental Figure 1C), while the IC_{50} value of H1975OR was 2μM (Supplemental Figure 1C). The signatures of resistant H1975OR cells were identified with activated Notch signaling and mutant KRAS status (Supplemental Figures 1D, E), which was applied for correlation analysis in detail (Supplemental Figure 1F).

The established Osimertinib resistant adenocarcinoma cells of H1975OR were analyzed for gene-type signatures, as was illustrated in Supplemental Figure 2. The overall view of the differentially expressed non-coding RNAs was embedded in the heat map (Supplemental Figure 3A), and the dysregulated miRNAs were chosen for their significant abnormalities (GSE184980). The box plot showed the distribution of RNA intensities in the six samples referring to quality control (Supplemental Figure 3B), and the distribution of normalized intensities was almost the same for the miRNAs (Supplemental Figure 3C). The horizontal comparisons were made referring to the regulated miRNAs. Given that only the miRNAs exhibited the most significant differences, the selected miRNAs were double-checked with qPCR detection (Supplemental Figure 3D), of which, hsa-Let-7b and hsa-Let-7d were suppressed greatly in Osimertinib resistant H1975OR cells.

A Volcano plot exhibited the differences in miRNA expression as marked with red and blue tags (Supplemental Figure 3E). The meaningful prediction of the GO terms and pathways were chosen and ranked according to enrichment scores, and the most significantly enriched biological process terms were regulative transcription and small molecular metabolic processes (Supplemental Figure 3F, Left). The most significantly enriched cellular component terms are located in the nucleus and cytoplasm (Supplemental Figure 3F, middle). The most significantly enriched molecular function terms were protein binding (Supplemental Figure 3F, right). GO analysis was applied for predicting and analyzing the possible functional pathways in which altered miRNAs may participate, and Let-7b was set as the potential candidate for future studies.

**Osimertinib Resistant Lung Adenocarcinoma Cells Harbored Decreased Let-7 Family of miRNAs and Notch Signaling**

The H1975 cell line bearing T790M/L858R mutations was selected for its resistance to first generation TKIs, and the HCC827 cell line bearing sensitive EGFR mutations was selected for another test group. We successfully established the Osimertinib resistant H1975OR cells and HCC827OR cells (Figure 1A). The samples of lung Adenocarcinoma from the TCGA database (Pan-Cancer Atlas/Firehose Legacy) were analyzed with mutation and CNA data. Notch signaling participants were universally activated, and the detailed expression patterns were illustrated in a heat map (Figure 1B). Notch signaling activation correlated with the stem cells’ renewal and therapy resistance, thus, we then explored the co-activation of EGFR signaling and Notch signaling. Key functional factors of Notch signaling were primarily screened (Figure 1C), which were correlated with poorer survival expectance (Supplemental Figure 4A), and the results were confirmed by western blotting in resistant lung cancer cells (Figure 1D and Supplemental Figure 5). We also detected the inverse relationship between Let-7b and key Notch signaling activators (Figure 1E, Data Source: StarBase v3.0), Let-7b, alone,
indicated better survival expectancy in lung adenocarcinoma, but failed in lung squamous cancer (Supplemental Figures 4B, C).

Let-7b decreased significantly in Osimertinib resistant H1975OR and HCC827OR cells (Figure 1F), strongly suggesting the inverse interaction between Let-7b and Notch signaling associated treatment resistance.

**Resistant Lung Adenocarcinoma Consists of More Stem-Like Cells**

The phenotype of ALDH1A1 positive cells was identified and treated as the stem cells group, with the ability of higher self-renewal, determining the poorer survival expectancy. Resistant H1975OR cells and HCC827OR cells consisted of more ALDH1A1+ cells than primary cells (Figures 2A, B), which could form many more spheres than the adjacent cells (data not shown). Moreover, the ALDH1A1 cells group was naturally resistant to Osimertinib, and the proliferative differences were not significant when receiving Osimertinib (Figure 2C).

Similarly, Let-7b decreased significantly in stem cells of spheres (Figure 2D), and we confirmed that the stem cells group was responsible for therapy resistance, and therefore detected the Notch signaling characteristics in spheres of H1975 and HCC827 stem cells (Figure 2E and Supplemental Figure 6), and the functional levels of EGFR and Notch signaling activators were much higher in the stem cells of spheres, which harbored stemness signatures (Figure 2F and Supplemental Figure 7).

**Metformin Sensitized the Osimertinib Resistant Cells by Decreasing the Stem Cells Ratio**

The H1975OR cells and HCC827OR cells responded better to Osimertinib than the control groups when culturing with 5 mmol of Metformin (Figure 3A). Moreover, when the sphere cells of H1975 and HCC827 were co-cultured with Metformin, the proliferative index also decreased (Figure 3B). To further locate the implicated mechanisms, we found that Metformin decreased the ratios of ALDH1A1 cells in the group receiving Osimertinib, indicating that stem cells accounted for therapy
resistance, which could be attenuated by Metformin (Figure 3C). Moreover, we noticed that the stem cell ratio did not change as significantly as the combination group when using Metformin alone, indicating its assistant role, but not dominant role in facilitating therapy response.

Metformin Sensitization of Osimertinib Resistant Cells Was Dependent on Mature Let-7b Overexpression

The let-7 family of Let-7a, Let-7b, and Let-7d were detected when receiving combined Metformin and Osimertinib, and Let-7b increased significantly in the resistant cells group (Figure 4A). The functional miRNAs of mature patterns were processed by a nuclear microprocessor complex composed of DGCR8/DROSHA (17, 18), and were then exported to the cytoplasm as RNA induced silencing complex (RISC) to perform certain functions. We found inconsistent levels of pri-let-7b and pre-let-7b, indicating that Metformin functioned through perturbing the let-7b maturation (Figure 4B). Since methyltransferase plays a key role in microRNA maturation by catalyzing m6A formation (19–23), we examined expression levels of Methyltransferase-like 3 (METTL3), Methyltransferase-like 14 (METTL14), and Wilms tumor 1-associated protein (WTAP), three components of the writer protein complex in m6A process. Metformin increased the METTL3 expression significantly (Figure 4C and Supplemental Figure 8), and the METTL3 alone remarkably decreased pri-Let-7b and increased both pre-Let-7b and Let-7b-5p (Figure 4D). Similarly, knocking down METTL3 abolished the Metformin effects of induction of Let-7b-5p overexpression in H1975OR cells (Figure 4E, above) and HCC827OR cells (Figure 4E, below).
Metformin Promotes the METTL3 Mediated Let-7b Maturation by Suppressing the Promoter Methylation Level

JASPAR analysis indicated the possible CpG islands upstream of the METTL3 locus (Figure 5A, http://www.urogene.org/methprimer/), and the cells treated with Metformin had significantly lower methylation within this CpG island compared to cells without the exposure (Figure 5B). Quantitative chromatin immunoprecipitation (ChIP) assays showed that Metformin effectively reduced the bindings of DNA methyltransferase (DNMT)-3a and DNMT-3b to the METTL3 promoter (Figure 5C). To determine how the METTL3 activates the Let-7b maturation, m6A-specific RNA immunoprecipitation (RIP) coupled qRT-PCR analysis was performed, and the effects of METTL3-mediated m6A on the pri-Let-7b maturation revealed that m6A-pri-Let-7b decreased greatly when the Osimertinib resistant cells received the Metformin (Figure 5D). Further, we identified that enforcing either DNMT3a or DNMT3b into the H293T cells could reduce the m6A-pri-Let-7b levels (Figure 5E). NKAP and HNRNPA2B1 were both defined as crucial m6A readers to perform the final functional process (24–26), and results showed that both NKAP and HNRNPA2B1 bound with m6A-Let-7b significantly, and m6A-Let-7b existed with DGCR8 and DROSHA to perform maturation functions (Figure 5F and Supplemental Figure 9). Similarly, RIP-coupled qRT-PCR indicated the bindings between NKAP/HNRNPA2B1 and m6A-Let-7b in H1975OR (Figure 5G, left) cells and HCC827OR cells (Figure 5G, right).

Increased Let-7b Was Critical for Re-Sensitizing the Osimertinib Treatment and Was Dependent on Inactivating Notch Signaling

To determine the critical role of Let-7b in Metformin induction of Osimertinib sensitization, Let-7b expression was manipulated, and inhibitors referring to Let-7b greatly abolished the Metformin effects in resistant cells (Figure 6A) and stem cells
(Figure 6B) when receiving Osimertinib, with Notch signaling re-activation (Figure 6C and Supplemental Figure 10). Similarly, Let-7b inhibition specifically diminished the Metformin decreasing of stem cells group (Figures 6D, E), and these results proved the dominant role of Let-7b in Metformin affected functional signaling. The regulative connections and the mechanistic m6A regulation of Let-7 were illustrated as a scheme (Figure 6F).

DISCUSSION

Therapeutics resistance has always been an issue when fighting against cancer, and a large number of studies have attempted to search for drug resistance-related genes (27, 28). Generally, chemotherapy and radiotherapy perished most cancer cells in cycles of treatments, however, steady cells with lower proliferation ability successfully survived. These silent cells did not react to agents admiring the rapidly proliferating cells. The cancer group consisted of heterogeneous sub-clones, and the cancer stem cells, also known as initiating cells and stem-like cells, were related to cancer initiation, progression, resistance, and recurrence. However, the reaction of stem cells and the changes in their gene signatures to targeted therapy with TKIs has never been explored.

TKIs targeting EGFR are used to treat lung cancer patients with EGFR amplification and mutations. They have significantly improved the survival of the treated patient population. They also improved the quality of life for these patients. However, most patients will inevitably develop the disease progression and TKI resistance (29, 30). Usually, when the L858R/T790M mutation emerges, the third generation such as Osimertinib can be used to prolong the survival time and control the disease progression. However, there is no strategy or TKIs available to treat or overcome Osimertinib resistance. We studied the non-coding RNAs' profile and stem cells' characteristics to reveal the latent mechanisms relating to Osimertinib resistance. Panels referring to non-coding RNAs were all analyzed, and several candidates with
aberrant expressions were detected. Further, to explore the contribution of cancer stem cells to Osimertinib therapy resistance, we checked the proliferation ratio and re-confirmed the candidate miRNAs levels in the stem cells group. The ALDH1A1 cells exhibited similar miRNAs characteristics, and were originally resistant to Osimertinib, suggesting that the stem cells group may be the core force of group resistance. We further identified that the Notch signaling was activated in lung adenocarcinoma in the resistant tumors. Notch signaling is critical for maintaining proliferation and EMT-related stem cells’ initiation.

Metformin was reported to sensitize the TKIs’ effects, but its roles were unclear with unidentified mechanisms, and its facilitation referring to Osimertinib has not been explored. We first confirmed the sensitization of Metformin enforcing on Osimertinib and primarily revealed the mature miRNAs signatures of the Osimertinib resistant H1975 and HCC827 cells. Methylation was one of the RNA modifications patterns, among which, N6-methyladenosine (m6A) was mostly explored for its abundance in messenger RNA (mRNA) and non-coding RNAs. m6A modification, methylated adenosine at the N6 position (31, 32) is a dynamic and reversible process caused by

![FIGURE 5](image-url)
cellular transformation, environmental hypoxia, or mutations accumulation (33–35), and regulates RNA transcription, processing, splicing, degradation, and translation (36, 37). However, its roles in non-coding RNAs were not clear. Functional m6A was accomplished with the assistance of writers, erasers, and readers, and in this study, we found the Osimertinib resistant lung cancer cells could be re-sensitized when adding Metformin, and resistant cancer stem cells were induced to renewal inhibition. Let-7b was selected as one representative inhibitor and could be stimulated when adding Metformin, contributing to Notch signaling inactivation. m6A writers included the methyltransferase complex, of which, the METTL3 could affect the miRNAs maturation by catalyzing the m6A formation in RNAs. Metformin increased the main

FIGURE 6 | Let-7b was critical for sensitizing the Osimertinib treatment. Let-7b inhibition greatly abolished the Metformin effects in resistant cells (A) and in stem cells (B) when receiving Osimertinib, with Notch signaling re-activation (C), the grouping of gels/blots were cropped from different parts, and the full-length gels could be referred to in the Supplemental Data. (D, E) Let-7b inhibition specifically diminished the Metformin decreasing of stem cells group. (F) The regulative connections and the mechanistic m6A regulations of Let-7 were generated and drawn by PowerPoint and were illustrated as one image. *P < 0.05.
members of the m6A writers. Among these, METTL3 decreased the pri-Let-7b and increased both the pre-Let-7b and mature Let-7b, which was illustrated in the schematic figure.

In conclusion, we identified one novel and effective strategy to enhance the TKIs’ response therapy, and the participation of Metformin decreased the bindings of DNMT3a/b to the METTL3 promoter with the help of the readers of NKarP and HNRNPA2B1. Together, the mediation of m6A formation on pri-Let-7b processing increased the mature Let-7b, whose key role is to suppress the Notch signaling and to re-captivate the Osimertinib treatment. Future in vivo studies will help to confirm the beneficial effects of Metformin usage prior to clinical trials. We revealed the maturation processing signaling filled up the methylation regulation of the miRNAs, which may dominate in alleviating the therapy resistance, and bring the prospective future for lung cancer treatments.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request. The established Osimertinib resistant adenocarcinoma cells of H1975OR were analyzed for gene-type signatures, which could be viewed at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE184980.

AUTHOR CONTRIBUTIONS
KL: Bioscientific experiments, Cells culturing. SG: Experimental tests, RNA/Protein tests. LM: Bioscientific experiments, Study designation. Z-YP: Experimental tests, Cells culturing. YS: Bioscientific experiments, Study designation. ND: RNA/Protein tests, Figures preparation. JW: Paper drafting, RNA/Protein tests, Statistical analysis, Database screening, Figures preparation. HR: Study designation, Statistical analysis. ST: Paper drafting, Study designation, Statistical analysis, Images quality control. XS: Paper drafting, Study designation, Statistical analysis, Database screening, Figures preparation, References cross checking. All authors contributed to the article and approved the submitted version.

FUNDING
This experiment was supported by the National Science Foundation for Young Scientists of China, grant No. 81602597 (Referred to Xin Sun), National Science Foundation for Young Scientists of China, Grant No.82003140 (Referred to Guo-Dong Xiao). Foundation Research Project of Shaanxi Province, 2021SF-117 (Referred to XS). The Natural Science Basic Research Program of Shaanxi, No. 2018JM7017 (Referred to XS).

ACKNOWLEDGMENTS
We appreciate and thank Mallory Ellis and Dr. Leslie Robinson for their careful revisions and editing, polishing the language in the manuscript. The authors acknowledge assistants in the Center for Translational Medicine, Cancer Center of the First Affiliated Hospital of Xi’an Jiaotong University, and appreciate the technical assistance provided by all staff of the Thoracic Department. We also appreciate the crucial technical assistance and resource support from Dr. Guodong Xiao.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.731561/full#supplementary-material

Supplementary Figure 1 | RNA-panel analysis with gene ontology description and functional signaling predication. (A) More than 5000 non-coding RNAs were differentially expressed between the H1975 and H1975OR cells, and the representative heat map results were listed for illustrating the miRNAs, lncRNAs, circRNAs differences. (B) The distribution of RNA intensity in H1975 cells and H1975OR cells was confirmed. (C) Samples were detected triplicate for person correlation referring to quality control. (D) The abnormally expressed miRNAs were rechecked by qRT-PCR, and the expression variations of miRNAs were compared between qRT-PCR and microarray analysis results. (E) The volcano plot exhibited statistically significant differences in miRNAs expression. (F) Functional predication indicated the location and the pathways that alternative miRNAs may contribute to in the cellular biology and cancer initiation. (G) Signaling pathways that altered miRNAs may interact with were carried out with qRT-PCR analysis.

Supplementary Figure 2 | The sensitivity of Osimertinib in treating Lung adenocarcinoma harboring mutant EGFR. The sensitivity analysis was carried out using shared data of Genomics of Drug Sensitivity in Cancer at the SANGER site. The Osimertinib sensitivity referring to lung cancer samples of PAN data was drafted with Z-score (A) and was rankly exhibited in table (B). (C) H1975 cells were sensitive to Osimertinib with concentration much lower than IC50. (D) EGFR mutant lung cancer cells are very sensitive to Osimertinib treatment, comparing to that of lung cancer cells with wild type EGFR. (E) Adenocarcinoma cells with Kas-Mut mutation were resistant to Osimertinib with much higher IC50 score. (F) Most of the Notch signaling associated factors were primarily identified with resistance.

Supplementary Figure 3 | Establishing the Osimertinib resistant cells. (A) Osimertinib was dissolved in dimethyl sulfoxide (DMSO), and a total of 1×106 cells/ml of H1975 cells were seeded in a 6-wells plate and incubated in RPMI-1640 medium containing Osimertinib. The initial concentrations of Osimertinib were started with a concentration equal to the half-maximal inhibitory concentration of H1975 cells. After a cycle of Osimertinib treatment, only a small percentage of cells were sensitive to Osimertinib with concentration much lower than IC50. (B) The abnormally expressed miRNAs were rechecked with qRT-PCR and were then harvested for RNAs analysis. (D) The images of gene probes detection were exhibited for illustration.

Supplementary Figure 4 | Clinical significance of Notch signaling and Let-7b. Notch signaling factors of ADAM10, ADAM17, APH1A, APH1B, ARFDC1, CIR1, CTBP1, CTBP2, CUL1, DLL1, DLL3, DLL4, DTX1, DTX2, DTX3, DTX1, DTX4, EP300, HDAC1, HDAC2, HEJ1, HEJ5, HEY1, ITOH, JAG1, JAG2, KDM6A, LFNG, MAML1, MAML2, MAML3, MAML5, NCOR2, NCOA2, NCSTN, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NRP1, NUMB, NUMB2, PSEN1, PSEN2, PSENEN, RPBJ, RPBJL, RRFNQ, SNW1, SPEN, HES2, HES4, HES7, HEY1, HEY2, were selected for analyzing in two studies of Lung Adenocarcinoma (TCGA, Firehouse Legacy), and in Lung Adenocarcinoma (TCGA, Pan-Cancer Atlas). (A) Altered Notch signaling indicates shorter survival time, comparing to cases without Notch functional alternation. The clinical significance of Let-7b in patients with NSCLC was analyzed, and relative higher expression of Let-7b correlated with better survival expectancy
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clin (2018) 68 (6):394–424. doi: 10.3322/caac.21492

2. Chen S-S, Li K, Wu J, Peng Z-Y, Wang Z-D, Wang J-C, et al. Stem Signatures Associated Antibodies Yield Early Diagnosis and Precise Prognosis Predication of Patients With Non-Small Cell Lung Cancer. J Cancer Res Clin Oncol (2020) 147(1):223–33. doi: 10.1007/s00432-020-03325-4

3. Chang W, Wang H, Kim W, Liu Y, Deng H, Liu H, et al. Hormonal Suppression of Stem Cells Inhibits Symmetric Cell Division and Gastric Tumorigenesis. Cell Stem Cell (2020) 26(5):739–54.e8. doi: 10.1016/j.stem.2020.01.020

4. Sun X, Li K, Zhao R, Sun Y, Xu J, Peng Z-Y, et al. Lung Cancer Pathogenesis and Poor Response to Therapy Were Dependent on Driver Oncogenic Mutations. Life Sci (2021) 265:118797. doi: 10.1016/j.lfs.2021.118797

5. Parascandola M, Xiao L. Tobacco and the Lung Cancer Epidemic in China. Tobacco Lung Cancer Res (2019) 8(Suppl 1):S1–30. doi: 10.21037/tlcr.2019.03.12

6. Hong Q-Y, Wu G-M, Qian G-S, Hu C-P, Zhou J-Y, Chen I-A, et al. Prevention and Management of Lung Cancer in China. Cancer (2015) 121 (S17):3080–8. doi: 10.1002/cncr.29584

7. Bode AM, Dong Z, Wang H. Cancer Prevention and Control: Alarming Challenges in China. Natl Sci Rev (2016) 3(1):117–27. doi: 10.1093/nsr/nrw054

8. Cai W-Y, Wei T-Z, Luo Q-C, Wu Q-W, Liu Q-F, Yang M, et al. The Wnt Signaling Pathway Regulates the Expression of let-7 miRNAs in Lung Cancer Cells. Cell Physiol Biochem (2016) 38(4):1232–40. doi: 10.1159/000445460

9. Sun X, Li K, Zhao R, Sun Y, Xu J, Peng Z-Y, et al. Lung Cancer Pathogenesis and Poor Response to Therapy Were Dependent on Driver Oncogenic Mutations. Life Sci (2021) 265:118797. doi: 10.1016/j.lfs.2021.118797

10. Parascandola M, Xiao L. Tobacco and the Lung Cancer Epidemic in China. Tobacco Lung Cancer Res (2019) 8(Suppl 1):S1–30. doi: 10.21037/tlcr.2019.03.12

11. Hong Q-Y, Wu G-M, Qian G-S, Hu C-P, Zhou J-Y, Chen I-A, et al. Prevention and Management of Lung Cancer in China. Cancer (2015) 121 (S17):3080–8. doi: 10.1002/cncr.29584

12. Bode AM, Dong Z, Wang H. Cancer Prevention and Control: Alarming Challenges in China. Natl Sci Rev (2016) 3(1):117–27. doi: 10.1093/nsr/nrw054

13. Cai W-Y, Wei T-Z, Luo Q-C, Wu Q-W, Liu Q-F, Yang M, et al. The Wnt Signaling Pathway Regulates the Expression of let-7 miRNAs in Lung Cancer Cells. Cell Physiol Biochem (2016) 38(4):1232–40. doi: 10.1159/000445460

14. Sun X, Li K, Zhao R, Sun Y, Xu J, Peng Z-Y, et al. Lung Cancer Pathogenesis and Poor Response to Therapy Were Dependent on Driver Oncogenic Mutations. Life Sci (2021) 265:118797. doi: 10.1016/j.lfs.2021.118797

15. Parascandola M, Xiao L. Tobacco and the Lung Cancer Epidemic in China. Tobacco Lung Cancer Res (2019) 8(Suppl 1):S1–30. doi: 10.21037/tlcr.2019.03.12

16. Xiao G, Zhang B, Meng J, Wang J, Xu C, Tang S-C, et al. miR-367 Stimulates Wnt Cascade Activation Through Degradating FBXW7 in NSCLC Stem Cells. Cell Cycle (2017) 16(24):2374–85. doi: 10.1080/15384101.2017.1380136

17. Sun X, Liu J, Xu C, Tang SC, Ren H. The Insights of Let-7 miRNAs in Oncogenesis and Stem Cell Potency. J Cell Mol Med (2016) 20(9):1779–88. doi: 10.1111/jcmm.12861

18. Sun X, Tang S-C, Xu C, Wang C, Qin S, Du N, et al. Dicer1 Regulated Let-7 Expression Levels in P53-Induced Cancer Cell Death Requires Cyclin D1. J Cell Mol Med (2015) 19(6):1357–65. doi: 10.1111/jcmm.12522

19. Yan G, Yuan Y, He M, Gong R, Lei H, Zhou H, et al. M6a Methylation of Precursor-miR-320/RUNX2 Controls Osteogenic Potential of Bone Marrow-Derived Mesenchymal Stem Cells. Mol Ther - Nucleic Acids (2020) 19:421–36. doi: 10.1016/j.omtn.2019.12.001

20. Si W, Li Y, Ye S, Li Z, Liu Y, Kuang W, et al. Metthyltransferase 3 Mediated m6a Methylation Promotes Stress Granule Formation in the Early Stage of Acute Ischemic Stroke. Front Mol Neurosci (2020) 13:103. doi: 10.3389/fnmol.2020.00103

21. Mi B, Xiong Y, Yan C, Chen L, Xue H, Panayi AC, et al. Metthyltransferase-Like 3 Mediated N6-Methyladenosine Modification of miR-7212-5p Drives Osteoblast Differentiation and Fracture Healing. J Cell Mol Med (2020) 24 (11):6385–96. doi: 10.1111/jcmm.15284

22. Wang C-X, Cui G-S, Liu X, Xu K, Wang M, Zhang X-X, et al. METTL3-Mediated M6a Modification is Required for Cerebellar Development. PLoS Biol (2018) 16(6):e2004880. doi: 10.1371/journal.pbio.2004880

23. Engel M, Chen A. The Emerging Role of mRNA Methylation in Normal and Pathological Behavior. Genes Brain Behav (2018) 17(3):e12428. doi: 10.1111/gbb.12428

24. Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, et al. The Interplay Between M6a RNA Methylation and Noncoding RNA in Cancer. J Hematol Oncol (2019) 12(1):121. doi: 10.1186/s13045-019-0805-7

25. Zhao Y, Shi Y, Shen H, Xie W. M6a-Binding Proteins: The Emerging Crucial Performers in Epigenetics. J Hematol Oncol (2020) 13(1):35. doi: 10.1186/s13045-020-00872-8

26. Chen X-Y, Zhang J, Zhu J-S. The Role of M6a RNA Methylation in Human Cancer. Mol Cancer (2019) 18(1):103. doi: 10.1186/s12943-019-1033-z

27. Neel DS, Bivona TG. Resistance is Futile: Overcoming Resistance to Targeted Therapies in Lung Adenocarcinoma. NPJ Precis Oncol (2017) 1(1):3. doi: 10.1038/s41698-017-0007-0

28. Lin JJ, Wang ET. Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer (2016) 2(7):350–64. doi: 10.1016/j.trecan.2016.05.010

29. Muratza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, et al. Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. Cancer Res (2019) 79(4):689. doi: 10.1158/0008-5472.CAN-18-1281

30. Gao J, Li HR, Jin C, Jiang JH, Ding JY. Strategies to Overcome Acquired Resistance to EGFR TKI in the Treatment of non-Small Cell Lung Cancer. Clin Trans Oncol (2019) 21(10):1287–301. doi: 10.1007/s12094-019-02075-1

31. Huang H, Weng H, Chen J. M(6)A Modification in Coding and Non-Coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell (2020) 37 (3):270–88. doi: 10.1016/j.ccell.2020.02.004

32. Huang H, Weng H, Chen J. The Biogenesis and Precise Control of RNA M6a Methylation. Trends Genet (2020) 36(1):44–52. doi: 10.1016/j.tig.2019.10.011
33. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-Cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. *Cell Rep* (2017) 18(1):248–62. doi: 10.1016/j.celrep.2016.12.019

34. Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: An Integrated Repository Portal for Tumor–Immune System Interactions. *Bioinformatics* (2019) 35(20):4200–2. doi: 10.1093/bioinformatics/btz210

35. Ponsioen B, Post JB, Buissant des Amorie JR, Laskaris D, van Ineveld RL, Kersten S, et al. Quantifying Single-Cell ERK Dynamics in Colorectal Cancer Organoids Reveals EGFR as an Amplifier of Oncogenic MAPK Pathway Signalling. *Nat Cell Biol* (2021) 23(4):377–90. doi: 10.1038/s41556-021-00654-5

36. Zhang L, Hou C, Chen C, Guo Y, Yuan W, Yin D, et al. The Role of N6-Methyladenosine (M6a) Modification in the Regulation of circRNAs. *Mol Cancer* (2020) 19(1):105. doi: 10.1186/s12943-020-01224-3

37. Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, et al. The M6a Methyltransferase METTL3 Promotes Bladder Cancer Progression via AFF4/NF-kb/MYC Signaling Network. *Oncogene* (2019) 38(19):3667–80. doi: 10.1038/s41388-019-0683-z

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Gao, Ma, Sun, Peng, Wu, Du, Ren, Tang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.